Dedicated High-Performance Breast PET/CT

目的：建立一台高性能、高分辨率的PET/CT定量扫描仪 致力于乳房成像。这将允许验证自动代谢成像 乳房的局部分期、治疗反应的预测、随访 用于接受保守治疗的患者和乳房新药的开发 癌症治疗。 方法：采用新型高分辨率、低死区闪烁探测器设计 使用使用APD和PSPMT的双端读出方案和修改的版本 对于商用PET电子产品，我们将建造一台足够紧凑的PET扫描仪，以适合内部 我们现有的乳房CT扫描仪的机架。我们将结合这两个设备，以允许 在相同的临床环境下对乳房进行连续成像，从而准确地 注册的高分辨率功能和解剖图像。该设备将兼容 具有活组织检查工具，并将可扩展以便于胸壁和 腋毛。建设将分阶段进行。在每个阶段，我们将使用连续测试/重新测试 使用预先计算的基准的方法，允许高效和及时地解决 由此产生的问题。我们将使用最先进的图像重建技术 测量系统模型以最大限度地提高空间分辨率，我们将仔细实施 定量成像所需的所有数据校正。我们将比较性能 对30例确诊为乳腺癌的患者进行了全身PET/CT和MRI检查。 与健康相关：到目前为止，在诊所测试的乳房PET成像仪是低成本的， 不能在体内充分评估方法学的低性能设备，以及 不提供与3D解剖信息融合的3D图像(这是一种很好的技术- 在身体上得到证实)。因此，分子成像在分期和再治疗中的已知能力 分期、对治疗研究和药物开发的反应在很大程度上是不可用的 女性原发性乳腺癌患者的比例。提议的设备将解决这一问题 问题，并允许确定适当的最低成像要求 临床表现-将这项技术转化为患者护理的先决条件。

Objectives: To build a high-performance, high-resolution quantitative PET/CT scanner dedicated to imaging the breast. This will permit validation of anato-metabolic imaging of the breast in the contexts of local staging, prediction of therapeutic response, follow-up for patients receiving conservative therapy and the development of new drugs for breast cancer treatment. Methods: Using a novel high-resolution, low-dead-time scintillation detector design using a dual-ended read-out scheme using APDs and PSPMTs, and a modified version of commercial PET electronics, we will build a PET scanner compact enough to fit inside the gantry of our existing breast CT scanner. We will combine the two devices to allow sequential imaging of the breast in the same clinical setting, resulting in accurately registered high-resolution functional and anatomic images. The device will be compatible with biopsy tools and will be expandable to facilitate imaging of the chest wall and axillae. Construction will be phased. At each stage we will use a continuous test/re-test approach using pre-calculated bench-marks to permit efficient and timely resolution of arising issues. We will employ state-of-the-art image reconstruction techniques using measured system models to maximize spatial resolution, and we will carefully implement all necessary data corrections for quantitative imaging. We will compare performance with whole-body PET/CT and MRI in a trial of 30 patients with known breast cancer. Health relatedness: Breast PET imagers tested in the clinic to date are low-cost, low -performance devices that cannot adequately assess the methodology in vivo, and do not provide 3D images fused with 3D anatomic information (a technique that is well- proven in the body). Thus the known power of molecular imaging in staging and re- staging, response to therapy studies and drug development is not available to a large fraction of women with primary breast cancer. The proposed device will solve this problem and allow the determination of the minimum imaging requirements for adequate clinical performance - a pre-requisite for translation of this technology into patient care.